Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 12/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485453 | 0.80 | MAP3K5 (0.68) | MAP3K5MEN1LMNAKMT2ARET | |
| SCHEMBL3485929 | 0.77 | MAP3K5 (0.67) | MAP3K5MEN1KMT2ACDK2 | |
| SCHEMBL3486097 | 0.77 | MAP3K5 (1.00) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486350 | 0.76 | MAP3K5 (0.84) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486275 | 0.76 | MAP3K5 (0.76) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3486068 | 0.76 | MAP3K5 (0.65) | MAP3K5CDK2ALDH1A1 | |
| SCHEMBL3486443 | 0.75 | MAP3K5 (0.79) | MAP3K5RETCDK2GSK3BITK | |
| Hydrochloric Acid SCHEMBL3486202 | 0.74 | MAP3K5 (0.77) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL13862003 | 0.74 | MAP3K5 (0.67) | MAP3K5RETCDK2GSK3BITK | |
| SCHEMBL3485910 | 0.74 | MAP3K5 (0.77) | MAP3K5RETCDK2GSK3BITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | MAP3K5 42/4885MEN1 758/4885LMNA 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.